79491-46-6

Basic information

• Product Name: 2,6-dibroMo-3-Methoxy-5-nitropyridine
• Synonyms: 2,6-dibroMo-3-Methoxy-5-nitropyridine
• CAS NO: 79491-46-6
• Molecular Formula: C6H4Br2N2O3
• Molecular Weight: 311.91556
• Mol File: 79491-46-6.mol

Chemical Properties

• Melting Point: 113-114 °C(Solv: ligroine (8032-32-4))
• Boiling Point: 342.5±37.0 °C(Predicted)
• Appearance: /
• Density: 2.067±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -12.06±0.10(Predicted)
• CAS DataBase Reference: 2,6-dibroMo-3-Methoxy-5-nitropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-dibroMo-3-Methoxy-5-nitropyridine(79491-46-6)
• EPA Substance Registry System: 2,6-dibroMo-3-Methoxy-5-nitropyridine(79491-46-6)

Safety Data

• Hazardous Substances Data: 79491-46-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,6-dibromo-3-methoxy-5-nitropyridine is used as an intermediate in the synthesis of pharmaceuticals for its versatile chemical structure, which allows for the development of various drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
2,6-dibromo-3-methoxy-5-nitropyridine is used as a building block in the synthesis of agrochemicals, contributing to the development of new compounds with pesticidal or herbicidal properties to enhance crop protection and yield.
Used in Organic Synthesis:
2,6-dibromo-3-methoxy-5-nitropyridine is used as a key component in the synthesis of various organic compounds, leveraging its unique structural features to create a wide range of chemical entities for research and industrial applications.

Upstream product

• 79491-45-5 2,6-dibromo-3-methoxylpyridine 
• 109-00-2 3-HYDROXYPYRIDINE 
• 6602-33-1 2,6-dibromopyridin-3-ol 

Downstream Products

• 79491-48-8 2-bromo-5,6-dimethoxy-3-nitropyridine 
• 79491-49-9 3-amino-5,6-dimethoxypyridine 
• 79491-47-7 2,6-dibromo-5-methoxypyridin-3-amine 
• 64436-92-6 3-amino-5-methoxypyridine 

Relevant articles and documents

COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS

Disclosed herein are compounds of Formula I'. Compounds of Formula I' inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase- dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

Phosphoinositide-3-kinase inhibitors: Evaluation of substituted alcohols as replacements for the piperazine sulfonamide portion of AMG 511

Replacement of the piperazine sulfonamide portion of the PI3Kα inhibitor AMG 511 (1) with a range of aliphatic alcohols led to the identification of a truncated gem-dimethylbenzylic alcohol analog, 2-(5-(4-amino-6-methyl-1,3,5-triazin-2-yl)-6-((5-fluoro-6-methoxypyridin-3-yl)amino)pyridin-3-yl)propan-2-ol (7). This compound possessed good in vitro efficacy and pharmacokinetic parameters and demonstrated an EC50 of 239 ng/mL in a mouse liver pharmacodynamic model measuring the inhibition of hepatocyte growth factor (HGF)-induced Akt Ser473 phosphorylation in CD1 nude mice 6 h post-oral dosing.

Lead identification of benzimidazolone and azabenzimidazolone arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists

A knowledge-based library of 2,3-dichlorophenylsulfonyl derivatives of commercially available aryl amines was synthesised and screened as human CCR4 antagonists, in order to identify a suitable hit for the start of a lead-optimisation programme. Hits were required to be more potent than an existing indazole series, have better physicochemical properties (c log P 7.4 116 μg/mL), and be stable to acid and light. The benzimidazol-2-one core was identified as a hit suitable for further investigation. Substitution at N1 with small alkyl groups was tolerated; however, these analogues were inactive in the whole blood assay (pA2 7.4 (2.4), high LE (0.43), and solubility (152 μg/mL). In addition, 38 had human serum albumin binding of around 93% and met all the criteria for progression to lead optimisation.

Thiophene-imidazopyridines

The invention relates to thiophene-imidazopyridine compounds according to formula (I), wherein the substituents and symbols are as defined in the description. The compounds are inhibitors of PIk1

Synthetic Uses of the Sequential Ring Positional Reactivity in Pyridin-3-ol and Derivatives

A series of ring-substituted pyridin-3-ols has been prepared.The key to the scheme is the introduction of a bromo group to a specific ring position as a temporary blocking agent.As well as hydrogenolysis of the bromo function, nucleophilic displacement has also been investigated.